[ 會員# ] shenshifu
孕前基因檢查
請問現在有一種做産前基因檢測的技術來診斷未來嬰兒(BB)是否健康?想問題: 請問一下這種檢查有沒有作用?是怎樣的?謝謝。
王予婷醫生回覆:
7/31/2014
7/31/2014
Hello
Are you referring to non-invasive prenatal testing for the fetus?
I have taken for your reference an abstract from the RCOG Scientific Impact Paper No. 15
March 2014
‘Fetal genetic testing and aneuploidy diagnosis have until recently both needed invasive diagnostic
sampling procedures carrying a small but significant risk of miscarriage. In 1997 the presence of cell-free
fetal DNA (cffDNA) in the maternal circulation was reported.1 Fetal DNA comes from the placenta,2 can
be detected from the first trimester of pregnancy onwards3 and is rapidly cleared from the maternal
circulation after delivery.4 Maternal blood is therefore a reliable source of material for prenatal diagnosis.
However, the cffDNA is mixed with a larger proportion of maternal cell-free DNA and current
methodologies do not allow complete separation of fetal from maternal DNA in vitro. Therefore, the
first applications of this phenomenon focused on the detection, or exclusion of, paternally-inherited fetal
DNA sequences that are not present in the mother, such as Y chromosome sequences in pregnancies with
a male fetus or rhesus D (RhD) sequences in women who are RhD-negative. Recently, DNA sequencing
technologies have allowed very precise relative quantification of DNA fragments and so the detection of
the extra material resulting from fetal chromosome trisomy within the maternal plasma DNA can now
be performed in a robust manner.’
‘Non-invasive prenatal testing NIPT using maternal plasma DNA is available for several conditions. Obstetricians have used NIPT to guide management of women who are RhD-negative and whose fetuses are at risk of HDFN for many
years and guidelines should already reflect this change in practice. Fetal sex determination for clinical
indications in pregnancies at high sex-linked genetic risk is also established practice. Testing for
aneuploidy and especially Down syndrome by maternal plasma MPS is now available commercially but
while the test result is much more accurate than existing screening strategies, it is still not a diagnostic
assay. Hence, the term ‘non-invasive testing’ is currently used.’
These NIPT tests are available in the private clinics in Hong Kong.
Cheers,
Are you referring to non-invasive prenatal testing for the fetus?
I have taken for your reference an abstract from the RCOG Scientific Impact Paper No. 15
March 2014
‘Fetal genetic testing and aneuploidy diagnosis have until recently both needed invasive diagnostic
sampling procedures carrying a small but significant risk of miscarriage. In 1997 the presence of cell-free
fetal DNA (cffDNA) in the maternal circulation was reported.1 Fetal DNA comes from the placenta,2 can
be detected from the first trimester of pregnancy onwards3 and is rapidly cleared from the maternal
circulation after delivery.4 Maternal blood is therefore a reliable source of material for prenatal diagnosis.
However, the cffDNA is mixed with a larger proportion of maternal cell-free DNA and current
methodologies do not allow complete separation of fetal from maternal DNA in vitro. Therefore, the
first applications of this phenomenon focused on the detection, or exclusion of, paternally-inherited fetal
DNA sequences that are not present in the mother, such as Y chromosome sequences in pregnancies with
a male fetus or rhesus D (RhD) sequences in women who are RhD-negative. Recently, DNA sequencing
technologies have allowed very precise relative quantification of DNA fragments and so the detection of
the extra material resulting from fetal chromosome trisomy within the maternal plasma DNA can now
be performed in a robust manner.’
‘Non-invasive prenatal testing NIPT using maternal plasma DNA is available for several conditions. Obstetricians have used NIPT to guide management of women who are RhD-negative and whose fetuses are at risk of HDFN for many
years and guidelines should already reflect this change in practice. Fetal sex determination for clinical
indications in pregnancies at high sex-linked genetic risk is also established practice. Testing for
aneuploidy and especially Down syndrome by maternal plasma MPS is now available commercially but
while the test result is much more accurate than existing screening strategies, it is still not a diagnostic
assay. Hence, the term ‘non-invasive testing’ is currently used.’
These NIPT tests are available in the private clinics in Hong Kong.
Cheers,
以上資料只供參考,不能作診症用途,
請與家庭醫生查詢並作出適合治療。
如有身體不適請即求診,切勿延誤治療。
若資料有所漏誤,本網及相關資料提供者恕不負責。
請與家庭醫生查詢並作出適合治療。
如有身體不適請即求診,切勿延誤治療。
若資料有所漏誤,本網及相關資料提供者恕不負責。

潘淑燕 : 宮頸抹片細胞異常
病患者女 - 30歲 醫生你好,我七月驗左子宮頸抹片檢查,發現有不正常細胞,但沒有度數,現在很擔心變子宮.......Rain : 諮詢不能受孕的檢查方法
病患者女 - 39歲 王醫生,您好! 我今年39歲,和丈夫結婚10年了。前期因為生活關系,到近期才決定.......Yee77927 : 缺鐵性血貧血
病患者女 - 40歲 睇過醫生~ 驗血報告(缺鐵性血貧血),醫生說有可能月經量過多。唔知可以做什麼?.......miko159 : 月經不來
病患者女 - 25歲 月經8年先黎得果幾次,怎麼辦? .......Leewailam : 好像不正常?有病嗎?
病患者女 - 19歲 平均月經28日, 平均維持3天,上個月月經6/2~9/2, 經量頭兩天多第3日少及.......LK Chan : 卵巢水囊
病患者女 - 47歲 你好!最近婦檢發現卵巢有一個2.7cm的simple cyst。我沒有感到腹痛或其....... 發出提問使用細則
致王予婷醫生 提問